Granted Patent
B2
US 12,251,423 · App. 17/012,159 · Granted Mar 18, 2025
Method of effecting neuroprotection using soluble neuregulin isoforms
Assignee:
Mind-NRG Sàrl
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.
Claims (11)
1. A method of treating a subject suffering from schizophrenia, comprising intravenously administering to the subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β, wherein the recombinant soluble Type I Neuregulin-1 β isoform is the first 245, 246, 247, 248, 249, or 250 amino acids of Type I Neuregulin-1 β and is administered in an amount of about 400 ng/kg to about 600 ng/kg body weight of the subject to be treated.
2. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform is the first 245 amino acids of Type I Neuregulin-1 β.
3. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform crosses the blood-brain barrier.
4. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform reduces dopaminergic cell death in the subject compared to a subject that is not treated with the recombinant soluble Type I Neuregulin-1 β isoform.
5. The method of claim 1 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pl) of about 4 to about 10.
6. The method of claim 1 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modification is selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation, and any combination thereof.
7. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform is administered in an amount of 400 ng/kg to 600 ng/kg body weight of the subject to be treated.
8. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform is administered in an amount of about 400 ng/kg body weight of the subject to be treated.
9. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform is administered in an amount of about 600 ng/kg body weight of the subject to be treated.
10. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform is administered in an amount of 400 ng/kg body weight of the subject to be treated.
11. The method of claim 1 , wherein the recombinant soluble Type I Neuregulin-1 β isoform is administered in an amount of 600 ng/kg body weight of the subject to be treated.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 8, 2020
From: SCHRATTENHOLZ, ANDRÉ
To: PROTEOSYS AG
Reel/Frame 053707/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 8, 2020
From: PROTEOSYS AG
To: MIND-NRG SA
Reel/Frame 053707/0142 →
Continuity (6)
Division
12742983
Provisional Application
60988576
· Nov 16, 2007
References Cited (213)
US 5530109A
· Goodearl et al.
· 1996
[cited by applicant]
US 5763213A
· Ho et al.
· 1998
[cited by applicant]
US 5854220A
· Goodearl et al.
· 1998
[cited by applicant]
US 6087323A
· Gwynne
· 2000
[cited by examiner]
US 6147190A
· Goodearl et al.
· 2000
[cited by applicant]
US 7538197B2
· Schrattenholz
· 2009
[cited by applicant]
US 7763591B2
· Morishita
· 2010
[cited by applicant]
US 7919582B2
· Schrattenholz
· 2011
[cited by applicant]
US 20020045577A1
· Stefansson et al.
· 2002
[cited by applicant]
US 20040191818A1
· O'Toole et al.
· 2004
[cited by applicant]
US 20070213264A1
· Zhou
· 2007
[cited by examiner]
US 20100256066A1
· Schrattenholz
· 2010
[cited by applicant]
US 20140243269A1
· Schrattenholz
· 2014
[cited by applicant]
US 20140243270A1
· Schrattenholz
· 2014
[cited by applicant]
US 20140323408A1
· Schrattenholz
· 2014
[cited by applicant]
US 20150239948A1
· Schrattenholz
· 2015
[cited by applicant]
US 20210128687A1
· Schrattenholz
· 2021
[cited by applicant]
CA 2399452A1
· 2001
[cited by applicant]
EP 1252168A1
· 2002
[cited by applicant]
EP 1252186A2
· 2002
[cited by applicant]
JP H10509717A
· 1998
[cited by applicant]
WO WO1992020798
· 1992
[cited by applicant]
WO WO1996015812
· 1996
[cited by applicant]
WO WO199630403
· 1996
[cited by applicant]
WO WO1999018976
· 1999
[cited by applicant]
WO WO2001057051
· 2001
[cited by applicant]
WO WO2001058948
· 2001
[cited by applicant]
WO WO2003014156
· 2003
[cited by applicant]
WO WO03014156A2
· 2003
[cited by examiner]
WO WO2006008118
· 2006
[cited by applicant]
WO WO2006008119
· 2006
[cited by applicant]
WO WO2007062594
· 2007
[cited by applicant]
WO WO2007076701
· 2007
[cited by applicant]
WO WO2007113361
· 2007
[cited by applicant]
WO WO2007113366
· 2007
[cited by applicant]
WO WO2009062750
· 2009
[cited by applicant]
Pontieri et al (PNAS 92: 12304-12308, 1995).
[cited by examiner]
Porrino LJ (Psychopharmacology 112: 343-351, 1993).
[cited by examiner]
Rushe et al (Schizophrenia Res 35: 85-96, 1999).
[cited by examiner]
Falls (Exp Cell Res 284: 14-30, 2003).
[cited by examiner]
Kastin et al (J Neurochem 88: 965-970, 2004).
[cited by examiner]
Schillo et al (J Proteome Res 4: 900-908, 2005).
[cited by examiner]
Marchionni et al (Cold Spring Harb Symp Quant Biol 61: 459-472, 1996).
[cited by examiner]
Archer et al., “Effects Of Acute Administration Of Da Agonists On Locomotor Activity: Mptp Versus Neonatal Intracerebroventricular 6-0hda Treatment”, Neurotox Res., 2003; 5(1-2), pp. 95-110 (Abstract).
[cited by applicant]
Arnold et al., “Neurodevelopment, Neuroplasticity, And New Genes For Schizophrenia,” Prog Brain Res 147:319-345, 2005.
[cited by applicant]
Aviles-Olmos et al., “Exenatide And The Treatment Of Patients With Parkinson's Disease,” The Journal Of Clinical Investigation, 123(6), pp. 2730-2736 (2013).
[cited by applicant]
Bao J. et al., (2004) Activity-Dependent Transcription Regulation Of Psd-95 By Neuregulin-1 And Eos., Nat. Neurosci 7:1250-1258 (2004).
[cited by applicant]
Ben-Baruch et al., “Neu Differentiation Factors: a Family of Alternatively Spliced Neuronal and Mesenchymal Factors (43746)”, P.S.E.B.M., vol. 206, pp. 221-227, 1994.
[cited by applicant]
Benzel et al., “Interactions Among Genes In The Erbb-Neuregulin Signalling Network Are Associated With Increased Susceptibility To Schizophrenia,” Behav Brain Funct 3:31 (2007).
[cited by applicant]
Bertram et al., “Immunohistochemical Evidence For Impaired Neuregulin-1 Signaling In The Prefrontal Cortex In Schizophrenia And In Unipolar Depression,” Ann N Y Acad Sci 1096:147-156 (2007).
[cited by applicant]
Blackwood et al., “Are Some Genetic Risk Factors Common To Schizophrenia, Bipolar Disorder And Depression?Evidence From DISC1, GRIK4 And NRG1,” Neurotox Res 11:73-83 (2007).
[cited by applicant]
Boissier et al., (1966) [On The Potentiation Of Dopa Effects By Monoamine Oxidase Inhibitors], Psychopharmacologia 8:428-436.
[cited by applicant]
Bordi et al., “Effects of the Metabotropic Glutamate Receptor Antagonist MCPG On Spatial and Context-Specific Learning,” 1996, Neuropharmacology 35: 1557-1565.
[cited by applicant]
Britsch, “The Neuregulin-1/Erbb Signaling System In Development And Disease,” Adv Anat Embryol Cell Biol 190:1-65 (2007).
[cited by applicant]
Buonanno et al., “Neuregulin And Erbb Receptor Signaling Pathways In The Nervous System,” Curr Opin Neurobiol 11:287-296 (2001).
[cited by applicant]
Buresova et al., “On-Demand Platform Improves Accuracy Of The Morris Water Maze Procedure,” J Neurosci Methods 15:63-72 (1985).
[cited by applicant]
Burgess et al., “Biosynthetic Processing Of Neu Differentiation Factor. Glycosylation trafficking, and regulated cleavage from the cell surface,” Journal Of Biological Chemistry, vol. 270, No. 32, Issue Of Aug. 11, p. 1…
[cited by applicant]
Cabantchik et al., “Iron Chelation For Diseases Of Regional Siderosis”, Blood, (2013) vol. 122, No. 21, p. 3435.
[cited by applicant]
Cannella B. et al., “The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in chronic relapsing model for multiple sclerosis” Proc. Natl. Acad. Sci. USA, 1998, vol. 95, p.…
[cited by applicant]
Carlsson et al., “Systemic Administration Of Neuregulin-1 beta1 Protects Dopaminergic Neurons In A Mouse Model Of Parkinson's Disease,” 2011, Journal Of Neurochemistry 117: 1066-1074.
[cited by applicant]
Caudle et al., “Glutamate, Excitotoxicity, And Programmed Cell Death In Parkinson Disease,” 2009, Exp Neural., 220 (2), p. 230-3.
[cited by applicant]
Chew et al., “Regulation Of Ion Channel Expression In Neural Cells By Hormones And Growth Factors”, Molecular Neurobiology, vol. 18, 1998, p. 175-225.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT00943748, Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease (FAIR-PARK-I), Jul. 20, 2009.
[cited by applicant]
Costall et al., “Modulation Of Amphetamine Hyperactivity By Dpi Injected Into Rat Nucleus Accumbens [Proceedings],” Br J Pharmacol (1978) 64:461P.
[cited by applicant]
Damulin, “Pathogenic, Diagnostic And Therapeutic Aspects Of Vascular Cognitive Impairment,” Consilium Medicum vol. 8, No. 8, 2006.
[cited by applicant]
Dauer and Przedborski, “Parkinson's Disease: Mechanisms And Models,” 2003, Neuron vol. 39, 889-909.
[cited by applicant]
Davis et al., “Chronic Parkinsonism Secondary To Intravenous Injection Of Meperidine Analogues,” Psychiatry Research 1979;1(3):249-54.
[cited by applicant]
Devos et al., “Targeting Chelatable Iron As A Therapeutic Modality In Parkinson's Disease,” Antioxid Redox Signal, Jul. 10, 2014;21(2):195-210.
[cited by applicant]
Eberhardt et al., “Toxin Models Of Parkinsonism”, Eurekah Report, Landes Biosciences, 2007, pp. 153-173.
[cited by applicant]
Eilam et al., “Activity-Dependent Regulation Of Neu Differentiation Factor/Neuregulin Expression In Rat Brain,” Proceedings Of The National Academy Of Sciences Of The USA vol. 95, Feb. 1998 (Feb. 1998), pp. 1888-1893, X…
[cited by applicant]
Esper et al., (2006) “Neuregulins: Versatile Growth And Differentiation Factors In Nervous System Development And Human Disease,” Brain Res Rev 51:161-175.
[cited by applicant]
Esposito et al., “Non-Steroidal Anti-Inflammatory Drugs In Parkinson's Disease,” Jun. 2007, Experimental Neurology 205(20):295-312.
[cited by applicant]
Fallon et al., “Constitutive Activation Of The Neuregulin-1/Erbb Signaling Pathway Promotes The Proliferation Of A Human Peripheral Neuroepithelioma Cell Line”, 2004, Journal Of Neuro-Oncology 66: 273-284.
[cited by applicant]
Falls, “Neuregulins: Functions, Forms, And Signaling Strategies,” 2003, Experimental Cell Research 284:14-30.
[cited by applicant]
Falquet et al., “The Prosite Database, Its Status In 2002,” Nucleic Acids Res (2002) 30:235-238.
[cited by applicant]
Farmer et al., “The Genetics Of Bipolar Affective Disorder,” Curr Opin Psychiatry (2007) 20:8-12.
[cited by applicant]
Fazzini et al., “GM1 Gangliosides Alter Acute MPTP-Induced Behavioural And Neurochemical Toxicity In Mice,” Journal Of The Neurological Sciences, vol. 99 (1), (1990), 59-68 (Abstract).
[cited by applicant]
Feigin et al., “Recent advances in Huntington's disease: implications for experimental therapeutics,” 2002, Curr. Opin. Neurol. 15(4): 483-489.
[cited by applicant]
Final rejection issued by the United States Patent and Trademark Office for U.S. Appl. No. 12/742,983, filed Sep. 24, 2012, 13 pages.
[cited by applicant]
Final rejection issued by the United States Patent and Trademark Office for U.S. Appl. No. 12/742,983, filed Jun. 9, 2014, 16 pages.
[cited by applicant]
Fischbach, “NRG1 And Synaptic Function In The CNS,” Neuron (2007), 54:495-497.
[cited by applicant]
Genbank Aaa58639.1, “Heregulin-Beta1 [
[cited by applicant]
Gerlach et al., “Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man”, J Neural Transm, 1996, 103(8-9) pp. 987-1041 (Abstract).
[cited by applicant]
Geuna et al., (2007), “Nerve Regeneration Along Bioengineered Scaffolds,” Microsurgery 27:429-438.
[cited by applicant]
Gilert and Machluf, “Nano To Micro Delivery Systems: Targeting Angiogenesis In Brain Tumors,” Journal Of Angiogenesis Research 2:20 (2010), 1 Page.
[cited by applicant]
Glabe, “Biomedicine. Avoiding Collateral Damage In Alzheimer's Disease Treatment,” Science (2006), 314:602-603.
[cited by applicant]
Go et al., “Neuregulin-1 Polymorphism In Late Onset Alzheimer's Disease Families With Psychoses,” Am J Med Genet B Neuropsychiatr Genet. (2005), 139:28-32.
[cited by applicant]
Golub et al., “Behavioral Characteristics Of A Nervous System-Specific Erbb4 Knock-Out Mouse,” Behav Brain Res (2004), 153:159-170.
[cited by applicant]
Graus et al., “Antibodies And Neuronal Autoimmune Disorders Of The CNS”, J. Neurol., Apr. 2010;257(4):509-17.
[cited by applicant]
Gresham-Smith et al., Oxford Handbook Of Clinical Pharmacology And Pharmacotherapy, Moscow, “Meditsina”, 2000, p. 136-137.
[cited by applicant]
Guo et al., “Neuroprotective Effects Of Neuregulin-1 In Rat Models Of Focal Cerebral Ischemia,” Brain Res (2006), 1087:180-185.
[cited by applicant]
Haddaad and Sharma, “Adverse Effects Of Atypical Antipsychotics: Differential Risk And Clinical Implications,” CNS Drugs (2007), 21:911-936.
[cited by applicant]
Hahn et al., “Altered Neuregulin 1-Erbb4 Signaling Contributes To Nmda Receptor Hypofunction In Schizophrenia,” Nat Med 12:824-828 (2006).
[cited by applicant]
Halliday et al., “Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms”, Clin Exp Pharmacol Physiol 27(1-2): 1-8, 2000.
[cited by applicant]
Hanninen et al., “Interleukin-1 Beta Gene Polymorphism And Its Interactions With Neuregulin-1 Gene Polymorphism Are Associated With Schizophrenia,” Eur Arch Psychiatry Clin Neurosci Feb. 2008; 258(1)10-5. Epub Sep. 27, …
[cited by applicant]
Ho et al., “Sensory And Motor Neuron-Derived Factor”. The Journal Of Biological Chemistry. vol. 270. No. 24, Issue Of Jun. 16, p. 14523-14532, 1996.
[cited by applicant]
Hoglinger et al., “The pRb/E2F Cell-Cycle Pathway Mediates Cell Death In Parkinson's Disease,” Proc Natl Acad Sci USA 104:3585-3590 (2007).
[cited by applicant]
Hoglinger et al., “Dopamine Depletion Impairs Precursor Cell Proliferation In Parkinson Disease,” Nat Neurosci 7:726-735 (2004).
[cited by applicant]
Holbro, T. and Hynes “ErbB Receptors: Directing Key Signaling Networks Throughout Life,” Annu Rev Pharmacol Toxicol (2004), 44:195-217.
[cited by applicant]
Hong, “Evidence Of Missense Mutations On The Neuregulin 1 Gene Affecting Function Of Prepulse Inhibition,” Biol Psychiatry, Jan. 1, 2008; 63(1): 17-23. Doi:10.1016/j.biopschy.2007.05.011.
[cited by applicant]
Hu et al., “Bace1 Modulates Myelination In The Central And Peripheral Nervous System,” Nat Neurosci (2006) 9:1520-1525.
[cited by applicant]
Hutter et al., “BL-1023 Improves Behavior And Neuronal Survival In 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice”, Neuroscience, (2011), 180:293-304.
[cited by applicant]
Imamachi et al., “The Non-NMDA Glutamate Receptor Antagonist CNQX Augments Lidocaine Antinociception Through A Spinal Action In Rats,” Anesth Analg; 1999, 89:416-21.
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion issued by the International Searching Authority for Application No. PCT/EP2008/009715, dated May 18, 2010, 7 pages.
[cited by applicant]
International Search Report issued by the International Searching Authority for Application No. PCT/EP2008/009715, dated Jul. 29, 2009, 4 pages.
[cited by applicant]
Jane et al., “Stereospecific Antagonism By (+)-a-Methyl-4-Carboxyphenylglycine (MCPG) of (1S, 3R)-ACPD-Induced Effects In Neonatal Rat Motoneurones And Rat Thalamic Neurones”, Neuropharmacology 1993, 32:725.
[cited by applicant]
Joyce et al., “Low Dose Pramipexole Is Neuroprotective In The Mptp Mouse Model Of Parkinson's Disease, And Downregulates The Dopamine Transporter Via The D3 Receptor”, BMC Biology, 2004, 2:22, pp. 1-12.
[cited by applicant]
Kani et al., “The Extracellular Domains Of ErbB3 Retain High Ligand Binding Affinity At Endosome pH And In The Locked Conformation”, Biochemistry, 2005, 44:15842-15857.
[cited by applicant]
Karoutzou et al. “The Myelin-Pathogenesis Puzzle In Schizophrenia: A Literature Review,” Mol Psychiatry 13:245-260 (2008).
[cited by applicant]
Kastin et al., “Neuregulin-1-β1 enters Brain and Spinal Cord by Receptor-mediated transport” Journal of Neurochemistry, 2004, 88: 965-970.
[cited by applicant]
Kim et al., “Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease,” Journal of Endocrinology (2009), 202, 431…
[cited by applicant]
Kwon et al., “Neuregulin-1 Reverses Long-Term Potentiation At CA1 Hippocampal Synapses,” J Neurosci (2005), 25:9378-9383.
[cited by applicant]
Langston et al., “Evidence Of Active Nerve Cell Degeneration In The Substantia Nigra Of Humans Years After 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Exposure”, Ann Neurol. Oct. 1999; 46(4):598-605.
[cited by applicant]
Langston et al., “MPTP-Induced Parkinsonism In Human And Non-Human Primates—Clinical And Experimental Aspects.” Acta Neurol Scand Suppl. 1984;100:49-54 (Abstract).
[cited by applicant]
Li et al., “ErbB4, a receptor of the schizophrenia-linked protein neuregulin-1, controls glutamatergic synapse maturation and plasticity,” Neuron 54:583-597 (2007).
[cited by applicant]
Liberatore et al., “Inducible Nitric Oxide Synthase Stimulates Dopaminergic Neurodegeneration In The MPTP Model Of Parkinson Disease,” Nat Med 5:1403-1409 (1999).
[cited by applicant]
Lu et al., “Post-Translational Processing Of Membrane-Associated Neu Differentiation Factor Proisoforms Expressed In Mammalian Cells,” The Journal Of Biological Chemistry, vol. 270, No. 9, Issue Of March 3, pp. 4775-478…
[cited by applicant]
Lu et al., “Studies On The Structure And Function Of Glycosylated And Nonglycosylated Neu Differentiation Factors”, The Journal Of Biological Chemistry, vol. 270, No. 9, Issue Of March 3, p. 4784-4791, 1995.
[cited by applicant]
Mahajan et al., “Immunological Assays For Chemokine Detective In In-Vitro Culture Of CNS Cells,” 2003, Biol Proced Online 5(1): 90-102.
[cited by applicant]
Malenka and Nicoll, “Long-Term Potentiation—A Decade Of Progress?,” Science 1999, 285: 1870-1874.
[cited by applicant]
Marchionni et al., “Neuregulins As Potential Drugs For Neurological Disorders,” 1996, Cold Spring Harbor Symposia On Quantitative Biology, vol. Lxi, Cold Spring Harbor Laboratory Press, 61:459-472.
[cited by applicant]
Matthew et al., “Alpha7 Nicotinic Acetylcholine Receptor mRNA Expression And Binding InPostmortem Human Brain Are Associated With Genetic Variation In Neuregulin 1,” Hum Mol Genet. 16(23):2921-2932 (2007).
[cited by applicant]
Mcintosh et al., “The Effects Of A Neuregulin 1 Variant On White Matter Density And Integrity,” Mol Psychiatry Nov. 2008; 13(11):1054-1059. Epub Oct. 9, 2007.
[cited by applicant]
Meeks et al., “The Neurobiology Of Neuropsychiatric Syndromes In Dementia,” Curr Opin Psychiatry (2006), 19:581-586.
[cited by applicant]
Meyer-Luehmann et al., “Exogenous Induction Of Cerebral Beta-Amyloidogenesis Is Governed By Agent And Host,” Science 313:1781-1784 (2006).
[cited by applicant]
Meyer et al., “Isoform-specific expression and function of neuregulin,” Development, vol. 124, pp. 3575-3586, 1997.
[cited by applicant]
Mirapex. Label Information. Aug. 2012, 20 Pgs.
[cited by applicant]
Morris, “Synaptic Plasticity And Learning: Selective Impairment Of Learning In Rats And Blockade Of Long-Term Potention In Vivo By The N-Methyl-D-Aspartate Receptor Antagonist AP5,” Journal Of Neuroscience, 1989, 9(9):3…
[cited by applicant]
Muller and Schwarz, “Schizophrenia As An Inflammation-Mediated Dysbalance Of Glutamatergic Neurotransmission,” Neurotox Res (2006), 10:131-148.
[cited by applicant]
Muraulirishnan and Mohanakumar, “Neuroprotection By Bromocriptine Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Neurotoxicity In Mice,” FASEB Journal (1998) Jul. 12(10):905-912.
[cited by applicant]
Nadri et al., (2007), “Oxygen Restriction Of Neonate Rats Elevates Neuregulin-1alpha Isoform Levels: Possible Relationship To Schizophrenia,” Neurochem Int 51:447-450.
[cited by applicant]
Niceprot View Of Swiss-Prot: Q15491, Oct. 9, 2004.
[cited by applicant]
Odin et al., “Efficacy And Safety Of High-Dose Cabergoline In Parkinson's Disease”, Acta Neurol Scand, (2006), 113 (1) pp. 18-24 (Abstract).
[cited by applicant]
Office Action in U.S. Appl. No. 11/991,219, filed Dec. 14, 2012, 17 pgs.
[cited by applicant]
Office Action in U.S. Appl. No. 12/742,983, filed Mar. 23, 2012, 13 pgs.
[cited by applicant]
Office Action in U.S. Appl. No. 12/742,983, filed Sep. 20, 2013, 8 pgs.
[cited by applicant]
Owen et al., “The Genetic Deconstruction Of Psychosis,” Schizophr Bull (2007), 33:905-911.
[cited by applicant]
Okazi et al., “Neuregulin-B Induces Expression Of An Nmda-Receptor Subunit,” Nature, vol. 390, Dec. 18/25, 1997, pp. 691-694.
[cited by applicant]
Ozaki M, Itoh K, Miyakawa Y, Kishida H, Hashikawa T (2004) “Protein Processing And Releases Of Neuregulin-1 Are Regulated In An Activity-Dependent Manner,” J Neurochem 91:176-188.
[cited by applicant]
Parlodel, Label Information, Updated Jan. 2012, 17 Pgs.
[cited by applicant]
Pertusa et al., “Transciptional Control Of Cholesterol Biosynthesis In Schwann Cells By Axonal Neuregulin 1,” J Biol Chem Sep. 28, 2007;282(39):28768-78.
[cited by applicant]
Phillips, “The Challenge Of Gene Therapy And DNA Delivery,” J Pharm Pharmacol 2001, 53: 1169-1174.
[cited by applicant]
Press Release, Boehringer Ingelheim “Once-Daily Mirapex Er Now Approved By Fda For Both Early And Advanced Parkinson's Disease”, Mar. 2010, 4 Pgs.
[cited by applicant]
Przedborski and Vila,(2003), “The 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model: A Tool To Explore The Pathogenesis Of Parkinson's Disease,” Ann N Y Acad Sci 991:189-198.
[cited by applicant]
Raabe et al., “Localization of neuregulin isoforms and erbB receptors in myelinating glial cells,” Glia, vol. 45, pp. 197-207, 2004.
[cited by applicant]
R & D Systems, “Recombinant Human Nrg1-B1/Hrg1-B1 Extracellular Domain, Catalog No. 377-Hb/Cf,” www.Rndsystems.Com. Apr. 27, 1993, 1 page.
[cited by applicant]
Radde et al., “Abeta42-Driven Cerebral Amyloidosis In Transgenic Mice Reveals Early And Robust Pathology,” Embo Rep 7:940-946 (2006).
[cited by applicant]
Rimer,“Neuregulin-1 Immunoglobulin-Like Domain Mutant Mice: Clozapine Sensitivity And Impaired Latent Inhibition,” Neuroreport 16:271-275 (2005).
[cited by applicant]
Ross et al., “Neurobiology Of Schizophrenia,” Neuron (2006), 52:139-153.
[cited by applicant]
Schillo et al., “Integrative Proteomics: Functional And Molecular Characterization Of A Particular Glutamate-Related Neuregulin Isoform,” J Proteome Res 4: 900-908, 2005.
[cited by applicant]
Schrattenholz and Soskic, “NMDA Receptors Are Not Alone: Dynamic Regulation Of NMDA Receptor Structure And Function By Neuregulins And Transient Cholesterol-Rich Membrane Domains Leads To Disease-Specific Nuances Of Glu…
[cited by applicant]
Schmidt and Ferger, “Neurochemical Findings In The Mptp Model Of Parkinson's Disease,” Journal Of Neural Transmission, (2001), 108 (11):1263-82. (Abstract).
[cited by applicant]
Schneider et al., “A Randomized, Controlled, Delayed Start Trial Of GM1 Ganglioside In Treated Parkinson's Disease Patients”, J. Neurol Sci, (2013), 324(1-2), pp. 140-148.
[cited by applicant]
Schubert, “Alzheimer Disease: Bace1 Branches Out,” Nat Med (2006), 12:1123.
[cited by applicant]
Scolnick et al., “Schizophrenia: Do The Genetics And Neurobiology Of Neuregulin Provide A Pathogenesis Model?,” Harv Rev Psychiatry (2006), 14:64-77.
[cited by applicant]
Sekiyama et al., “Structure-Activity Relationships Of New Agonists And Antagonists Of Different Metabotropic Glutamate Receptor Subtypes,” Br. J. Pharmacol. 1996, 117:1493-1503.
[cited by applicant]
Sheldon and Robinson, “The Role Of Glutamate Transporters In Neurodegenerative Diseases And Potential Opportunities For Intervention,” Neurochem Int., 51 (6-7), pp. 333-355 (2007).
[cited by applicant]
Shyu et al., “Neuregulin-1 Reduces Ischemia-Induced Brain Damage in Rats”, 2004, Neurobiology of Aging, 25(7), pp. 935-944.
[cited by applicant]
Sinemet, Label Information, Updated Jan. 2011, 13 pgs.
[cited by applicant]
Steece-Collier et al,. “Etiology of Parkinson's disease: genetics and environment revisited”, Proc Natil Acad Sci USA 15 (4): 483-489, 2002.
[cited by applicant]
Stefansson, H. et al., “Neuregulin 1 and susceptibility to schizophrenia” Am. J. Hum. Genet., 2002, vol. 71, p. 877-892.
[cited by applicant]
Summary of Product Characteristics (European Commission), Symmetrel Capsules, Feb. 19, 2014, 5 pgs.
[cited by applicant]
Swiss-Prot: Q15491, Oct. 9, 2004.
[cited by applicant]
Symmetrel, Label Information, Jan. 2009, 15 pgs.
[cited by applicant]
Tatton et al., “Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism”, J. Neurosci Res., Dec. 1991., 30(4), pp. 666-672 (Abstract).
[cited by applicant]
Teismenn et al., “Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease,” SYNAPSE 2001, 39:167-174.
[cited by applicant]
Thomson et al., “Association Of Neuregulin 1 With Schizophrenia And Bipolar Disorder In A Second Cohort From The Scottish Population,” Mol Psychiatry 12:94-104 (2007).
[cited by applicant]
Vidal et al., “Making Sense Of Antisense,” Eur J Cancer 2005, 41: 2812-2818.
[cited by applicant]
Vila and Przedborski, “Targeting Programmed Cell Death In Neurodegenerative Diseases,” Nat Rev Neurosci (2003), 4:365-375.
[cited by applicant]
Wang et al., “Contrasting Effects Of Mitogenic Growth Factors On Myelination In Neuron-Oligodendrocyte Co-Cultures,” Glia 2007, 55:537-545.
[cited by applicant]
Warren et al., “The N-Terminal Domains Of Neuregulin 1 Confer Signal Attenuation,” Journal Of Biological Chemistry Sep. 15, 2006, 281(37):27306-27316.
[cited by applicant]
Watkins and Collingridge, “Phenylglycine Derivatives As Antagonists Of Metabotropic Glutamate Receptors”, 1994, Trends Pharmacol. Sci.(vol. 15), pp. 333-342.
[cited by applicant]
Wen et al., “Structural And Functional Aspects Of The Multiplicity Of Neu Differentiation Factors,” Molecular And Cellular Biology, vol. 14, No. 3, Mar. 1994 (Mar. 1994), pp. 1909-1919, Xp002064746; Issn: 0270-7306; Abs…
[cited by applicant]
Wikipedia Article “Cnqx,” May 20, 2009.
[cited by applicant]
Wikipedia Article “Nifedipine”, Jan. 10, 2010.
[cited by applicant]
Wikipedia article “AP-5”, Dec. 18, 2009.
[cited by applicant]
Willem et al., “Control Of Peripheral Nerve Myelination By The Beta-Secretase BACE1,” Science (2006) 314:664-666.
[cited by applicant]
Wolpowitz et al., “Cysteine-Rich Domain Isoforms For The Neuregulin-1 Gene Are Required For Maintenance Of Peripheral Synapses,” Neuron 25(1):79-91, 2000.
[cited by applicant]
Woo et al., “Neuregulin-1 Enhances Depolarization-Induced Gaba Release,” Neuron (2007), 54:599-610.
[cited by applicant]
Xie et al., “Association of PSD-95 with ErbB4 facilitates neuregulin signaling in cerebellar granule neurons in culture,” Journal of Neurochemistry 100:62-72 (2007).
[cited by applicant]
Xu et al., “Neuroprotection By Neuregulin-1 Following Focal Stroke Is Associated With The Attenuation Of Ischemia-Induced Pro-Inflammatory And Stress Gene Expression,” Neurobiol Dis 19:461-470 (2005).
[cited by applicant]
Xu et al., “Neuregulin-1 Is Neuroprotective And Attenuates Inflammatory Responses Induced By Ischemic Stroke,” Biochem Biophys Res Commun (2004), 322:440-446.
[cited by applicant]
Xu Z. et al., “Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke” Journal of Cerebral Blood Flow & Metabolism, 2006, vol. 26, p. 527-535.
[cited by applicant]
Yang et al., “Neuregulin-Induced Expression of the Acetylcholine Receptor Requires Endocytosis of Erbb Receptors,” Mol Cell Neurosci (2005), 28:335-346.
[cited by applicant]
Yurek, D. M. et al., “Supranigral injection of neuregulin 1-β induces striatal dopamine overflow” Brain Research, 2004, vol. 1028, p. 116-119.
[cited by applicant]
Zelapar, Label Information, Feb. 2008, 19 Pgs.
[cited by applicant]
Zelapar, Label Information, updated Aug. 2014, 14 pages.
[cited by applicant]
Zhang L. et al., “Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures,” Journal of Neurochemistry, 2004, vol. 91, p. 1358-1368.
[cited by applicant]
Zhao et al., “Neuregulins Promote Survival and Growth of Cardiac Myocytes,” The Journal Of Biological Chemistry, 1998, vol. 273, No. 17, p. 10261-10269.
[cited by applicant]
Banks, A., “Characteristics of compounds that cross the blood-brain barrier,” BMC Neurol. Jun. 12, 2009;9 Suppl 1(Suppl 1):S3, 5 pages.
[cited by applicant]
Castillo et al., “Neuregulin-1 isoform induces mitogenesis, KCa and Ca2+ currents in PC12 cells. A comparison with sciatic nerve conditioned medium,” Brain Research (2006) 1110:64-75.
[cited by applicant]
Pankonin et al., “Specific Structural Features of Heparan Sulfate Proteoglycans Potentiate Neuregulin-1 Signaling,” The Journal of Biological Chemistry, Jan. 2005, vol. 280, No. 1, pp. 383-388.
[cited by applicant]
Rösler et al., “Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1,” Neuropharmacology (2011) 61:1413-1418.
[cited by applicant]
[Author Unknown] “Neuregulin 1” Wikipedia [online] https://en.wikipedia.org/w/index.php?title=Neuregulin_1&oldid=1215826496 (Access Date: Sep. 12, 2024); 18 pages.
[cited by applicant]
Buckel, P., “Recombinant Proteins for Therapy”, Tips (Dec. 1996); 17: 450-456.
[cited by applicant]
Stopford, C. L., et al., “Distinct Memory Profiles in Alzheimer's Disease”, Cortex (Oct. 2007); 43: 846-857.
[cited by applicant]
[Author Unknown, Date Unknown] “Parkinson's Disease Models”, Neuro Detective International; 4 pages.
[cited by applicant]
Emborg, M. E., “Evaluation of animal models of Parkinson's disease for neuroprotective strategies”, Journal of Neuroscience Methods (2004); 139(2): 121-143.
[cited by applicant]
Gündüz, B., et al., “The effects of leptin hormone on locomotor activity in Syrian hamsters (
[cited by applicant]
Lang, A. E., et al., “Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease”, Annals of Neurology (2006); 59(3): 459-466.
[cited by applicant]
Noel, N., et al., “Preclinical Characterization of MIN-301, a Neuregulin-1 Fragment, as a Potential Disease-Modifying Therapy for Parkinson's Disease”, Poster, Minerva Neurosciences Inc., ACNP Meeting (Dec. 6-10, 2015);…
[cited by applicant]
Rosenegger, D., et al., “A quantitative proteomic analysis of long-term memory”, Molecular Brain (2010); 3: 1-10.
[cited by applicant]
Sheikov, N., et al., “Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium”, Ultrasound in Medicine & Biology (2008); 34(7): 109…
[cited by applicant]
U.S. Appl. No. 12/742,983, Exhibit A: U.S. Appl. No. 10/495,132: Declaration of Dr. Akiko Ishida, signed Oct. 5, 2007; 9 pages.
[cited by applicant]
U.S. Appl. No. 12/742,983: Declaration of Prof. Andre Schrattenholz, signed Jul. 21, 2012; 11 pages.
[cited by applicant]
U.S. Appl. No. 12/742,983: Declaration of Prof. Andre Schrattenholz, signed Mar. 20, 2013; 8 pages.
[cited by applicant]
U.S. Appl. No. 15/333,959: Declaration of Amos Korczyn, signed Apr. 26, 2017, with Appendix 1; 146 pages.
[cited by applicant]
U.S. Appl. No. 16/420,755: Declaration of Remy Luthringer, signed Apr. 16, 2020, with Exhibit B and C; 21 pages.
[cited by applicant]